Results 21 to 30 of about 155 (115)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis

European Psychiatry, 2023
Introduction Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin ...
L. Samalin, L. Mekaoui, M. Rotharmel, P. de Maricourt, M.-A. Codet, E. Gaudre Wattinne   +5 more
doaj   +1 more source

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

European Psychiatry, 2021
Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/
E. Gaudre Wattinne, L. Mekaoui, M. Rothärmel, M.A. Codet, S. Bouju   +4 more
doaj   +1 more source

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine

International Journal of Methods in Psychiatric Research, 2022
Objective Derive and confirm factor structure of the Montgomery‐Åsberg Depression Rating Scale (MADRS) in patients with treatment‐resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment ...
Stephane Borentain, Jagadish Gogate, David Williamson, Thomas Carmody, Madhukar Trivedi, Carol Jamieson, Patricia Cabrera, Vanina Popova, Ewa Wajs, Allitia DiBernardo, Ella J. Daly   +10 more
doaj   +1 more source

Gender differences in response and remission rates among patients receiving esketamine

European Psychiatry, 2023
Introduction Depressive disorders are among the leading causes of disability. The lifetime risk for developing clinically significant depression is estimated around 15%.
A. T. Guterman, K. Feffer, A. Z. Gershi
doaj   +1 more source

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

European Psychiatry, 2021
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly
C. Gastaldon, E. Raschi, J. Kane, C. Barbui   +3 more
doaj   +1 more source

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression

European Psychiatry, 2022
Introduction Esketamine nasal spray has been developed to treat adults with treatment resistant depression. On Dec.2019, EMA granted a market access approval in this indication. Objectives ESKALE is a descriptive study of treatment resistant depression
S. Ludovic, M.A. Codet, M. Rotharmel, P. De Maricourt, J. Boursicot, E. Gaudre Wattinne   +5 more
doaj   +1 more source

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations

Neuropsychiatric Disease and Treatment, 2023
Allan H Young,1 Mohamed Abdelghani,2 Mario F Juruena,1,3 Viktoriya L Nikolova,1 Ramin Nilforooshan4,5 1Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 2Camden and Islington NHS Foundation Trust, London, UK ...
Young AH, Abdelghani M, Juruena MF, Nikolova VL, Nilforooshan R   +4 more
doaj  

Repurposing potential of ketamine: Opportunities and challenges

Indian Journal of Psychological Medicine, 2020
Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor which also interacts with various other receptors that account for its myriad actions.
C S Gautam, Sonia S Mahajan, Jatin Sharma, Harmanjit Singh, Jagjit Singh   +4 more
doaj   +1 more source

ESKETAMINE NASAL SPRAY FOR DEPRESSIVE PATIENTS

, 2023
Abstract: Ketamine can promptly reduce suicidality and relieve other serious symptoms of depression. Esketamine (Spravato), FDA approved is usually given as a nasal spray. It operates under “S” molecule. Ketamine can be administered intranasally (spray into the nose) for treating resistant mood disorders like depression.
openaire   +2 more sources

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression [PDF]

International Journal of Neuropsychopharmacology, 2022
Abstract Background In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)—short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)—were analyzed to evaluate the relationship between dissociation and ...
Chen, Guang, Chen, Li, Zhang, Yun, Li, Xiang, Lane, Rosanne, Lim, Pilar, Daly, Ella J, Furey, Maura L, Fedgchin, Maggie, Popova, Vanina, Singh, Jaskaran B, Drevets, Wayne C   +11 more
openaire   +2 more sources